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1. Introduction
1.1. General information
Helicobacter pylori  (H. pylori) is a spiral-shaped, Gram-negative, microaerophilic bacterium
inhabiting human gastric mucosa and playing an essential role in dyspepsia, gastritis, gastric
ulcer disease and duodenal ulcer disease [1-6]. Moreover, in 1994 the International Agency
for Research on Cancer of the World Health Organization (IARC/WHO) concluded that H.
pylori  is a class I carcinogen, involved in gastric cancer and mucosa-associated lymphoid
tissue (MALT) lymphoma [2, 7-11]. Furthermore, increasing number of studies showed the
association between H. pylori infections and pathogenesis of extragastric diseases. The most
convincing data appeared in case of iron-deficiency anemia (IDA) of unknown origin and
idiopathic thrombocytopenia purpura (ITP) [12].  Eradication of H. pylori  in IDA patients
resulted in  normalization of  hemoglobin level  while  in  ITP patients  lead to  a  favorable
platelet response [13].  Moreover,  the findings and ongoing research concerning H. pylori
infections suggest  its  association with other  diseases  such as:  heart  or  vascular  diseases
(ischemic heart disease, coronary artery disease, cardiac syndrome x), neurological diseases
(stroke, Alzheimer’s or Parkinson’s diseases) as well as obesity, diabetes mellitus, asthma
or diseases of oral mucosa [1, 14-18].
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H. pylori infection is one of the most common bacterial infections, with the estimated prevalence
reaching 50% of the human population worldwide. Nevertheless, the occurrence of H. pylori
infections correlate with the socioeconomic status and are often reflected in their geographical
distribution. The frequency of this infection is markedly higher in the developing countries
(80-90%) rather than in the developed countries (<40%) [4]. In Europe the incidence of H.
pylori varies and can be associated with geographical location and the percentage of compa‐
triots of non-European origin [19]. Current studies show the declining trend in the prevalence
of H. pylori infections in developed countries such as Denmark or Czech Republic [20, 21],
while the frequency of this infection in Asia–Pacific region ranges from 15.5% in Australia,
71.7% in Shanghai China, to 94.3% in Eastern Siberia [6].
The Polish multi-center study performed between 2000 and 2003 revealed that the incidence
of H. pylori infections was 84% in adult patients [22], whereas our research, conducted in
southern Poland between 2009 and 2011, showed that the rate of H. pylori infection among
adults was 23% [23].
H. pylori has evolved numerous strategies for survival in the gastric niche (especially due to
the release of urease, an enzyme, which increases the pH value of the environment around the
bacterial cells) [24]. Furthermore, the clinical course of H. pylori infection depends from both
the bacterial virulence factors and the host susceptibility (e.g. diet, genetic predispositions,
degree of the immune response to infection) [3, 7, 25].
It was concluded that untreated H. pylori infection led to acid-related disorders of the digestive
system. Great majority of individuals colonized by H. pylori developed co-existing chronic
gastritis, which in subsets of patients could evolve to duodenal or gastric ulcer as well as gastric
cancer [7, 8, 26, 27]. Experiments performed in animal models (Mongolian gerbils) confirmed
the progressive sequence of lesions from chronic gastritis to gastric cancer by gastric atrophy,
intestinal metaplasia, and dysplasia [28]. Figure 1 illustrates the sequential steps of diseases
resulting from H. pylori infection.
H. pylori infection significantly enhances the risk of development of peptic ulcer disease (up
to 15 times) as well as gastric cancer (up to 6 times) [1, 7, 24]. Peptic ulcer disease (PUD) –
gastric and/or duodenal ulcer – develops in about 15% of H. pylori infected patients, whereas
the progression to neoplastic lesions may occur only in a small fraction of patients with H.
pylori infection. Gastric cancer arises in about 1-5% of patients and MALT cancer in <1% of
infected subjects [7, 8, 27, 29].
The information presented above highlights the importance of an effective treatment against
H. pylori. Furthermore, the increasing resistance of H. pylori to antibiotics/chemotherapeu‐
tics  currently used in empirical  therapy justifies  the need for continuous surveillance of
antibiotic resistance as well as compliance to guidelines of the European Helicobacter Study
Group (EHSG) [1].
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Figure 1. Sequential steps of diseases resulting from H. pylori infection (based on fig. 3 Konturek et. al J Physiol Phar‐
macol. 2009 [8]).
1.2. Virulence factors (VF)
The pathogenesis of H. pylori is determined by wide spectrum of virulence factors, which can
be divided into two major groups:
1. VF secreted into the bacterial extracellular environment (e.g. immunogenic protein CagA,
vacuolating cytotoxin VacA, secreted enzymes: urease, aliphatic amidase, catalase,
oxidase, superoxide dismutase, phospholipases, glycosulfatase and proteolitic enzymes).
2. VF associated with the bacterial surface (e.g. outer membrane proteins, adhesins, flagella,
LPS) [24, 25].
CagA. One of the most important H. pylori virulence factors is highly immunogenic protein
CagA. It is encoded by cytotoxin associated gene (cagA gene), which is located on the cag
pathogenicity island (cag PAI) and carried by 56-90% of H. pylori strains [8, 24, 29-32]. CagA
protein (after translocation into the host cells by the type IV cag secretion system) stimu‐
lates epithelial cells to produce the following cytokines: interleukin IL-8 (strong chemotac‐
tic factor and activator of inflammatory process on the mucous membrane), IL-6, IL-1β, and
tumor necrosis factor α (TNF-α; enhances the inflammatory process) [31, 33, 34] and is also
responsible for changes in the host cells such as proliferation, motility,  and polarity [25,
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35].  Patients  infected  with  cagA  positive  strains  usually  exhibit  a  higher  inflammatory
response and are at a higher risk of developing gastric ulcer disease, atrophic gastritis, or
gastric cancer [3, 8, 24, 36, 37].
VacA. Another major H. pylori virulence determinant is vacuolating cytotoxin A (VacA). This
protein is involved in various mechanisms of programmed cell death (including apoptosis and
necrosis) in the target host cells [38]. While VacA encoding gene (vacA) occurs in almost all H.
pylori strains, only approximately 50% of isolates express active protein. Moreover, variations
in the vacA gene structure considering signal (s) as well as middle (m) region result in
differences in vacuolating activity of this cytotoxin [7, 8, 24, 34, 39]. H. pylori strains carrying
s1/m1 allelic form of vacA gene have higher vacuolating activity than isolates with s1/m2 or
s2/m1 alleles. Furthermore, polymorphisms among the vacA signal region (s1, s1a, s1b, s2) and
middle region (m1, m2) are also correlated with the intensity of inflammation process and the
severity of gastric epithelial cell injury, respectively. While strains possessing vacA s1a
genotype cause stronger inflammation process than isolates carrying vacA s1b or vacA s2
genotype, the strains harboring vacA m1 genotype cause more severe gastric epithelial cell
injury than the vacA m2 strains [34, 40]. Moreover, the infection with H. pylori strains possessing
vacA s1/m1 allele is strongly associated with peptic ulcer disease and gastric cancer [7, 40]. A
third polymorphic determinant of vacuolating activity of vacA gene was described in mid
region and termed the intermediate (i), but its role in the pathogenesis of H. pylori infection
remains debatable [41].
H. pylori is described as one of the most important risk factors contributing to the development
of gastric cancer in more than 50% of cases, while CagA and VacA as major virulence deter‐
minants play an important role in this process [2, 7, 8]. Due to the presence/absence of CagA
and VacA, H. pylori strains were divided into two types: type I (possessing cagA gene and
expressing vacuolating cytotoxin) and type II (lacking the cagA gene and with no expression
of vacuolating cytotoxin). Strains belonging to the type I (CagA+, VacA+ phenotype) are more
virulent, as their infections are associated with increased risk of peptic ulcer disease and gastric
cancer. Strains of the type II (CagA-, VacA- phenotype) are less virulent. Furthermore, an
intermediate type of H. pylori strain has been described. Isolates belonging to this group have
independent expression of CagA and VacA cytotoxins and represent a moderate level of
virulence [24, 34, 42].
Urease and aliphatic amidase. Remarkable capacity of H. pylori to colonize highly acidic
environment of stomach is mostly attributed to the production of urease. This enzyme
hydrolyzes urea (to ammonia and carbon dioxide), which results in an increase of pH value
in the environment surrounding the bacterium. A similar effect is produced by aliphatic
amidase, which also contributes to the pH value of the gastric environment [43]. Furthermore,
ammonia which is the product of enzymatic hydrolysis of urea, shows toxicity against
epithelial cells [24, 25, 32].
Other pathogenic enzymes.H. pylori produces many other groups of enzymes responsible for
the pathogenesis. While catalase, oxidase, and superoxide dismutase play a role in protecting
the bacterial cells from phagocytosis, phospholipase A2, phospholipases C, and glycosulfatase
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damage the cells of the mucous membrane [44-48]. Furthermore, H. pylori secretes numerous
proteolytic enzymes responsible for the gastric mucus degradation [49].
Adhesins. Adherence of H. pylori to the host cell receptors triggers cellular changes, which
include signal transduction cascades, leading to infiltration of inflammatory cells and to
persistence of the organism. H. pylori adhesins are proteins, glycoconjugates, or lipids, which
are involved in the initial stages of colonization by mediating the interactions between the
bacterium and the host cell surface (AlpA, AlpB, BabA, Hsp60, Hsp70, LPS core, LPS O antigen
(Lewis X), Nap) [8, 50, 51].
Outer membrane proteins. Outer inflammatory protein (OipA) is an outer membrane
inflammatory-related protein significantly associated with the development of duodenal
ulcers and gastric cancer. OipA plays an important role in induction of the mucosal cytokines
and in gastric mucosal inflammation [7, 8, 36]. The outer membrane proteins contributing to
the adherence of H. pylori are represented by: SabA, AlpAB [32, 36].
Flagella.H. pylori possess up to 6 unipolar flagella composed of two proteins: FlaA and FlaB
[24, 52]. Due to the flagella, H. pylori is motile and can move within stomach niche between
regions of low pH value to regions with higher pH value, which is more hospitable for these
bacteria [8, 53]. The motility is also necessary for the successful colonization of the stomach
mucosa [52].
LPS. Lipopolysaccharide of H. pylori is a unique and a potent immunogen. LPS of H. pylori
contains O-antigen structures, which resemble human glycosphingolipids due to the presence
of common host carbohydrate residues [54]. LPS contains structures like Lewis X and Lewis
Y antigens, which are similar to antigens of human blood groups, which occur also in the
human gastric epithelium. Due to molecular mimicry, bacteria are able to escape the host
immune response. Moreover, the specific structure of H. pylori LPS is crucial for the adhesion
to epithelial cells and colonization process of the human stomach by H. pylori [24, 54, 55].
While in the majority of people H. pylori colonization is asymptomatic, long-term carriage
significantly increases the risk of development of site-specific diseases [7, 8, 34, 36]. It was also
concluded that untreated H. pylori infection may lead to serious implications such as gastritis,
gastric ulcer disease and gastric cancer, therefore it is crucial to provide effective treatment.
Moreover, it was proved that introduction of early effective treatment of H. pylori infection in
cases of peptic ulcer disease can prevent these patients from developing gastric cancer [1, 26].
1.3. Treatment guidelines
Several recommendations concerning diagnosis and treatment regimen were issued as the
infection treatment is often unsuccessful. The first guidelines on diagnostic and therapeutic
approaches for the H. pylori infection were issued in the United States of America. The second
recommendations were introduced by Polish Society of Gastroenterology Helicobacter pylori
Working Group (PSG-E/HPWG) in 1996. The next guidelines of the PSG-E/HPWG on diag‐
nostic and therapeutic approaches for the H. pylori infection were issued in 2000, 2004 and 2008
[22, 56, 57]. The European Helicobacter Study Group (EHSG) took the initiative of introducing
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recommendations for the clinical management of H pylori infection in 1996 in Maastricht and
since then four consensus reports have been issued (1997, 2000, 2005, 2012) [1, 5, 58, 59].
Recommendations for the management of H. pylori infection are constantly evolving along
with the development of knowledge concerning this bacterium and its infections [1]. Current
guidelines on the management of H. pylori infections were produced by EHSG in 2012
(Maastricht IV/Florence Consensus Report) and should be introduced in the management of
this infection in European countries. Despite that fact, the recent Polish recommendations
issued in 2008 still support the Third Maastricht Consensus Report (2005). Nevertheless, the
new Polish guidelines are under development and will be issued in the near future.
The European Helicobacter Study Group and the Polish Society of Gastroenterology recom‐
mend therapeutic regimens, which include three types of drugs: 1) antisecretory (proton pump
inhibitors (PPI)), 2) cytoprotectants (drugs containing bismuth salts), and 3) antibiotics/
chemotherapeutics (clarithromycin, amoxicillin, metronidazole, tetracycline, levofloxacin, and
rifabutin) [1, 22].
The treatment regimens of H. pylori infections according to the PSG-E guidelines (2008) [22]
are presented in Table 1.
Treatment strategy Time of treatment
The First-Line Treatment (one of the following):
PPI, amoxicillin (1000 mg) and metronidazole (500 mg) twice a day
10–14 daysPPI, clarithromycin (500 mg), and metronidazole (500 mg) twice a day
PPI, amoxicillin (500 mg), and clarithromycin (500 mg) twice a day
The Second-Line Treatment (one of the following):
PPI, amoxicillin (1000 mg), and metronidazole (500 mg) twice a day and tetracycline (250
mg) three times a day
10–14 days
PPI, amoxicillin (1000 mg), and metronidazole (500 mg) twice a day and bismuth salts (120
mg) four times a day
The Third-Line Treatment:
Evaluation of the susceptibility of the strains to the currently used antimicrobial agents:
amoxicillin, metronidazole, clarithromycin, and tetracycline 14 days
(prolonged if the previous
treatments were shorter)Possible introduction of levofloxacin
Adding a probiotic
Table 1. Proposed strategy of the first, second and third – line treatment of H. pylori infection (table based on the
guidelines of PSG-E Consensus Report, 2008 [22])
According to the Maastricht IV/Florence Consensus Report guidelines, the treatment regimen
should be selected according to the areas of low (<20%) and high (>20%) clarithromycin
resistance, to provide the most effective therapy. Figure 2 presents the current EHSG guide‐
lines.
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PPI – proton pump inhibitor, CH – clarithromycin, MZ – metronidazole, AC – amoxicillin, LE – levofloxacin
Bismuth quadruple therapy: PPI, bismuth, metronidazole, and tetracycline (10 days)
Non-bismuth quadruple sequential therapy: 5-day period with PPI, amoxicillin, followed by 5-day period with PPI,
clarithromycin, and metronidazole (or tinidazole)
Non-bismuth quadruple concomitant therapy: clarithromycin, amoxicillin, and metronidazole + PPI (10-14 days)
Figure 2. Treatment schemes of Helicobacter pylori infection considering the regions of low and high prevalence of
clarithromycin-resistant strains (based on the Maastrich/Florence IV Consensus Report) [1].
In regions with high prevalence of resistance to clarithromycin (>20%), it is recommended
to abandon clarithromycin in the empirical treatment of H. pylori infections, if the antibiotic
susceptibility cannot be tested. As the first line empirical treatment, the bismuth–containing
quadruple therapy is recommended. If the bismuth salts are not available in certain countries
(e.g. Poland), then non-bismuth quadruple therapies (sequential or concomitant) could be
prescribed. Non-bismuth quadruple sequential therapy consists of 5-days of PPI plus amoxi‐
cillin, followed by 5-day period with PPI, clarithromycin, and metronidazole (or tinidazole),
whereas non-bismuth quadruple concomitant therapy comprises simultaneous use of clari‐
thromycin, amoxicillin, metronidazole, and PPI for 10-14 days. Although both non-bismuth
quadruple therapies contain clarithromycin, these regimens could be applied only as targeted
therapy based on testing of the bacterial susceptibility to clarithromycin. In regions, where
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bismuth salts are not available and high clarithromycin resistance occurs, targeted therapy
with clarithromycin seems to be the best option.
After failure of the first line treatment, the second line treatment regimen with PPI, levoflox‐
acin, and amoxicillin should be prescribed. It should be emphasized that levofloxacin cannot
be used in patients with chronic bronchitis or pneumonia, who may have taken fluoroquino‐
lones, hence it is recommended to perform susceptibility testing to levofloxacin. Moreover,
increasing resistance rate to antimicrobial agents should be taken into account [1], for instance
in Poland we noted an increasing resistance rate to levofloxacin [23]. Susceptibility testing
conducted before treatment, can protect against increasing resistance rate.
If the second line regimen failed, a third line treatment based on antimicrobial susceptibility
testing should be introduced. If susceptibility testing is not available, the empirical third line
regimen should contain antimicrobials not used previously. Except for the drugs already
mentioned, rifabutin is a therapeutic option (its use is limited to mycobacterial infections) [1].
Taking into account the EHSG recommendations, the rationale is to perform susceptibility
testing whenever possible to prevent the increase of drug resistance, especially in regions
where the resistance to clarithromycin is high.
1.4. Antimicrobial agents and bacterial resistance
Recent data show that combination of standard therapeutic strategies have lost some efficacy.
This fact is attributed to increasing antimicrobial resistance of H. pylori strains.
Clarithromycin. Among antimicrobial agents used in the treatment of H. pylori infections,
clarithromycin was considered to be one of the most effective drugs; nonetheless emergence
of clarithromycin resistance became the major risk factor of the treatment failure. In susceptible
strains, the eradication rates amounted to 87.7%, whereas in resistant strains the rates de‐
creased to 18.3% [5]. One of the most significant factors contributing to clarithromycin
resistance is the extensive use of macrolides, particularly in the treatment of upper and lower
respiratory tract infections in children [60]. Furthermore, studies conducted between 2001 and
2008 in 18 European countries confirmed the correlation between antibiotic resistance of H.
pylori strains and outpatient antibiotic consumption in adults. According to this multi-center
study, H. pylori clarithromycin resistance rates in Europe amounted to 17.5% and were
considerably higher in western/central and southern Europe (>20%) than in the northern
European countries (<10%) [61]. In Poland, the prevalence of H. pylori resistance to clarithro‐
mycin was 28% (data published by PSG-E) [22]. Nevertheless, according to our recent study
conducted in the years 2006-2008 and 2009-2011, resistance of H. pylori strains isolated in
southern Poland was also high and amounted to 34% and 22%, respectively [23, 62].
The major mechanism responsible for H. pylori clarithromycin resistance is associated with the
decrease in the binding of the antibiotic to the ribosome which is caused by the occurrence of
the point mutations within the peptidyltransferase-encoding region of 23S rRNA. The most
frequently reported point mutation is A-G transition at position 2143 (A2143G), which occurs
in 69.8% of H. pylori strains resistant to clarithromycin, while the less common mutations are
represented by A2142G and A2143C. Furthermore, other mutations, such as A2115G, G2141A,
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C2147G, T2190C, C2195T, A2223G, and C2694A, might also be associated with clarithromycin
resistance. Molecular assays have a significant impact on improving the availability and
accuracy of the data concerning H. pylori clarithromycin resistance, resulting in faster and
better selection of effective therapy [60, 63].
Metronidazole. Another antimicrobial agent, recommended in the therapy of H. pylori
infection is metronidazole. Metronidazole has a higher resistance rate than clarithromycin, but
it is of secondary importance and can be partly overcome. Treatment with this antimicrobial
agent is effective, however, with the exception of the regions where metronidazole resistance
reaches 40%. The resistance of H. pylori strains to metronidazole amounted to 34.9%, in Europe
[5, 61]. In Poland, the resistance rate to metronidazole is higher (46%), according to PSG-E data
(2008) [22], whereas in southern Poland, according to our recent study, it is 44% [62].
Common use of metronidazole in parasitic as well as gynecological diseases results in high
resistance rates of H. pylori strains isolated from both tropical residents and female patients
and contributes to overall resistance of the bacterium population [60].
Mechanism of metronidazole resistance in H. pylori is not completely understood and,
according to some authors, it is related to mutations in rdxA (which encodes an oxygen-
insensitive NADPH nitroreductase) and frxA genes (which encode NADPH flavin oxidore‐
ductase) [60, 64].
Levofloxacin. Levofloxacin is another antimicrobial agent recommended in H. pylori treat‐
ment, however rapid acquisition of levofloxacin resistance may contribute to the reduction of
its future efficiency. In Europe, the resistance rate of H. pylori to levofloxacin amounted to
14.4% between 2001 and 2008. Increasing rates of quinolone resistance are attributed to
frequent use of these agents in the therapy of the respiratory and urinary tract infections. While
in countries with lower quinolone consumption (e.g. Norway) the resistance rate of H. pylori
strains remains lower, in countries with high use of quinolones (e.g. Italy) the resistance rate
is higher [61]. According to data published by PSG-E, the population of H. pylori strains in
Poland is susceptible to ciprofloxacin [22]. Nevertheless, we reported that levofloxacin
resistance rate in southern Poland amounted to 16% in 2011 and in comparison with previous
years, the figure had grown [23].
The resistance to fluoroquinolones in H. pylori strains is due to the point mutations occurring
in gyrA gene at the 87 and 91 positions. Furthermore, some studies revealed a correlation
between the resistance to levofloxacin and norfloxacin and the point mutation in the position
463 of gyrB gene [60, 65].
Amoxicillin and Tetracycline. According to current surveys, the resistance to amoxicillin as
well as tetracycline is either very low or even absent, indicating their present clinical irrele‐
vance. While amoxicillin resistance is most likely associated with mutational changes in the
penicillin-binding encoding gene (pbpD), the tetracycline resistance is based on changes in
three nucleotides in the 16S rRNA (AGA 926-928→TTC) [22, 60, 62].
Rifabutin. Rifabutin is one of the antimicrobial agents recommended as an alternative in the
third line treatment, after two treatment failures. Prevalence of H. pylori resistance to this
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antibiotic is not well known but it is presumed to be very low, because its use is limited to
mycobacterial infection [1]. Moreover, rifabutin is very expensive and causes adverse events
like leukopenia, thrombocytopenia or clinically important impairment of liver functions [66,
67]. However, increase in rifabutin consumption may contribute to rapid emergence of
resistance. The mechanism of resistance to this antibiotic is mediated by mutations in the rpoB
gene [1, 60].
1.5. Resistance rate in Poland
Summing up the current and previous data concerning the prevalence of H. pylori resistance
in Poland, we revealed some differences. The results presented in Polish multi-center study
performed between 2000 and 2003 revealed that 28% of the analysed H. pylori strains were
resistant to clarithromycin, 46% to metronidazole, while all strains were susceptible to
amoxicillin and tetracycline [22].
Our studies conducted in the years 2006-2009 and 2010-2012 showed that the resistance rates
of H. pylori to clarithromycin in southern Poland were 34% and 22%, respectively [23, 62].
Moreover, we reported that the percentage of H. pylori strains resistant to metronidazole and
levofloxacin accounted for 44% and 6%, respectively. Furthermore, we confirmed the coexis‐
tence of resistance to more than one antimicrobial agent: a) resistance to metronidazole and
clarithromycin in 23% of the strains, b) resistance to metronidazole, clarithromycin, and
levofloxacin in 4% of the strains [62]. Additionally, in our recent studies we demonstrated that
in southern Poland the number of H. pylori strains resistant to levofloxacin increased signifi‐
cantly; from 5% in the years 2006-2008 to 16% in 2009-2011 [23].
As  it  was  previously  emphasized,  the  Maastricht  IV/Florence  Consensus  Report  recom‐
mends that  treatment regimen should be selected according to areas of  low (<20%) and
high (>20%) clarithromycin resistance [1]. Referring to available data concerning clarithro‐
mycin resistance rates in Poland, this country should be classified as a high clarithromy‐
cin resistance region [22, 23, 62].
Although the current Polish guidelines (PSG–E, 2008) on diagnostic and therapeutic ap‐
proaches to the H. pylori infection recommend clarithromycin in the first line treatment, the
rationale is to either abandon clarithromycin in an empirical treatment or apply clarithromycin
in therapy, but only with prior susceptibility testing.
2. Problem statement
Dynamic growth of H. pylori resistance to antimicrobial agents used in empirical treatment
becomes an increasingly important problem. While H. pylori resistance is often associated with
the antibiotic consumption and may vary according to region, it is recommended to constantly
monitor the resistance rates of this bacterium. Furthermore, in the areas of high clarithromycin
resistance rates as well as increasing resistance to other antibiotics/chemotherapeutics (used
in H. pylori treatment), it is worth consideration to replace empirical therapy with targeted
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therapy based on prior susceptibility testing. Moreover, early effective treatment of H. pylori
infection in patients with peptic ulcer disease can prevent gastric cancer.
3. Aplication area
Data concerning H. pylori resistance rates enable to introduce the most effective schemes of
infection treatment [5].
4. Research course
1. Monitoring of H. pylori resistance to antimicrobial agents used in empirical therapy
(according to the Maastricht IV/ Florence Consensus Report) in southern Poland.
2. Selection of the appropriate treatment regimen in H. pylori infections in southern Poland,
according to the current recommendations and local clarithromycin resistance rates
(Maastricht IV/ Florence Consensus Report).
3. Introduction of treatment guided by antimicrobial susceptibility testing in H. pylori
infections in southern Poland, taking into account: a) high level of clarithromycin
resistance, b) increasing resistance rates to levofloxacin, c) persisting high metronidazole
resistance rate.
4. Application of molecular method in detection of clarithromycin resistance.
5. Materials and methods
Clinical specimens. The study covered a group of 316 adult dyspeptic patients with thera‐
peutic indications for gastroscopy, who applied to the Falck Medycyna Outpatient Clinic of
Gastroenterology (Krakow, Poland) and the Chair of Gastroenterology, Hepatology and
Infectious Diseases, Jagiellonian University Medical College (Krakow, Poland).
All patients enrolled to the study underwent gastroscopy in the years 2010-2013. Two biopsy
specimens (one from antrum and the second from the body of the stomach) were taken from
each patient during gastroscopy. The biopsy specimens were transferred into transport
medium (Portagerm Pylori, bioMérieux, France) and transported to the laboratory (Depart‐
ment of Pharmaceutical Microbiology, Jagiellonian University Medical College, Krakow,
Poland) for further investigations.
Analysis of endoscopy and histopathological examination enabled to qualify patients into two
groups:
1. Subjects with peptic ulcer diseases (PUD) including individuals with peptic and/or
duodenal ulcers.
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2. Subjects with non-ulcerous dyspepsia (NUD) comprising patients without any patholog‐
ical changes found in endoscopy and patients with erosive and non-erosive diseases
including esophagitis, gastritis or duodenitis.
H. pylori microbiological culture and identification. Gastric biopsy specimens were homo‐
genized in glass sterile mortars and inoculated onto both non selective (Schaedler agar with
5% sheep blood, bioMérieux, France) and selective (Schaedler agar with 5% sheep blood and
selective supplement Dent, Oxoid, UK) media. Simultaneously, direct Gram-stained slides and
urease tests were performed from the biopsy specimens to confirm the presence of H. pylori.
The culture was carried out for 3 to 10 days under microaerophilic conditions at 37°C. The
cultured strains were identified according to:
1. Macroscopic appearance of the colonies;
2. Gram–stained slides prepared from bacterial colonies;
3. Biochemical tests (urease, catalase, and oxidase).
The study was approved by the Bioethical Commission of the Jagiellonian University (Krakow, Poland).
Before entering our study, each patient signed the informed consent document.
Susceptibility testing. Susceptibility of H. pylori strains to the recommended antimicrobial
agents (clarithromycin, metronidazole, levofloxacin, tetracycline, and amoxicillin) was
quantitatively assessed by the use of strips impregnated with antimicrobial agents gradient
(E-test, bioMérieux, France), which enabled to determine the minimal inhibitory concentration
(MIC). The colonies from pure H. pylori culture were suspended in 0.85% aqueous NaCl
solution in order to obtain an equivalent of 3.0 McFarland units. The bacterial suspension was
spread onto Schaedler agar medium with 5% sheep blood (bioMérieux, France) with sterile
cotton swabs. Single E-test stripes were applied onto the separate, inoculated agar plates and
incubated according to the manufacturer recommendations (E-test technical manual, bioMér‐
ieux, France).
Results of the susceptibility testing were interpreted according to EUCAST guidelines
(breakpoint values were presented in Table 2) [68].
Quality control of the susceptibility testing was performed with H. pylori ATCC 43504 strain.
DNA extraction.H. pylori culture (incubated for 72 hours on solid medium) was suspended in
1 ml of 0.85% aqueous NaCl solution and centrifuged (12000 rpm/3 min.). Genomic DNA was
extracted using the Sherlock AX isolation kit (A&A Biotechnology, Poland) according to the
manufacturer’s recommendations. DNA quantification was performed by spectrophotometry
at 260 nm. The purity of DNA was evaluated by the ratio of the absorbance at 260 and 280 nm
(A260/A280). The obtained DNA was stored at -20°C.
PCR identification of H. pylori. To confirm H. pylori microbiological identification, all
analysed strains were subjected to 16S rRNA PCR assay using primers HP-1 and HP-2
described by Kargar et al. [69]. PCR reaction was performed in a final volume of 25 µl
containing: 2 µl of genomic DNA, 2 µl of each primer, 5 µl of GoTaq® Flexi Buffer, 1.5 µl of
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MgCl2 (25 mM), 0.5 µl of PCR Nucleotide Mix (10 mM each), 0.125 µl of GoTaq® DNAPolymerase (5u/µl) and Nuclease-Free Water (Promega, USA). The following amplification
conditions were used: the initial denaturation at 95°C for 2 min., 35 cycles of 95°C for 60 s, 58°C
for 60 s, 72°C for 60 s and the final elongation at 72°C for 5 min. The expected 109-base-pair
PCR product was visualized after electrophoresis on an 2% agarose gel stained with ethidium
bromide.
cagA and vacA genes detection. The DNA from analysed H. pylori strains was subjected to
PCR assay detecting the cagA gene with the use of primers D008 and R008 described previously
by Chen et al. [70]. The PCR reaction was carried out as described above for the 16s rRNA PCR
assay. PCR cycling conditions consisted of initial denaturation at 94°C for 5 min., 33 cycles:
94°C for 60 s, 60°C for 60 s, 62.5°C for 60 s, 72°C for 60 s and the final elongation at 72°C for 5
min. The expected product of 298-base-pairs was visualized after agarose gel electrophoresis.
Furthermore, we performed the PCR assay to detect the vacA gene. A 229-base-pair fragment
of vacA was amplified with the primer pair VAC3624F and VAC3853R described previously
by Chisholm et al. [71]. The PCR reaction was carried out in the total volume of 25 µl as
described above. The following amplification conditions were used: the initial denaturation at
95°C for 2 min., 35 cycles of 95°C for 30 s, 53°C for 30 s, 72°C for 30 s and the final elongation
at 72°C for 5 min. The expected product was visualized after agarose gel electrophoresis.
Detection of clarithromycin resistance by RFLP-PCR analysis. The most prevalent point
mutations responsible for clarithromycin resistance (A2143G and A2142G) were detected by
PCR followed by RFLP analysis. A 425-base-pair fragment of the 23S rRNA was amplified with
the primers K1 and K2 described by Agudo et al. [63]. PCR amplification of DNA was
performed in a final volume of 25 µl as described above for the 16S rRNA PCR assay. The
cycling program was: 1 cycle at 95°C for 2 min.; 35 cycles of 95°C for 30 s, 60°C for 30 s, 72°C
for 30 s and a final elongation step at 72°C for 5 min. The amplicon was digested with Eco31I
(BsaI) enzyme (Thermo Scientific, USA) for 30 min. at 37°C and 5 min. at 65°C to detect A2143G
mutation [63] or with BbsI enzyme (New England Biolabs, USA) for 24 h at 37°C to detect
A2142G mutation [72]. The restriction products were analysed by electrophoresis on an 2%
agarose gel. Enzyme Eco31I digested the A2143G-positive H. pylori PCR amplicon into 304-
and 101-base-pair fragments, while BbsI enzyme cut the A2142G-positive H. pylori PCR
product into 332- and 93-base-pair fragments.
Antibiotic agent MIC breakpoints (mg/L)S ≤ R >
Amoxicillin 0.12 0.12
Clarithromycin 0.25 0.5
Levofloxacin 1 1
Metronidazole 8 8
Rifampicin 1 1
Tetracycline 1 1
Table 2. EUCAST clinical breakpoint for H. pylori [68].
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6. Results
Prevalence of H. pylori infection. Among 316 patients with dyspeptic symptoms admitted to
the study between November 2010 and June 2013, the presence of H. pylori infection was
confirmed in 73 cases (according to rapid urease test and bacterial culture). Therefore, the
prevalence of H. pylori infection in patients with dyspeptic symptoms from southern Poland
amounted to 23.1% (73/316). Taking into account the analysis of endoscopy and histopatho‐
logical examination among 73 H. pylori-positive patients, 26% (19/73) were qualified into the I
group (patients with PUD), whereas 74% (54/73) patients were qualified into the II group
(patients with NUD).
Susceptibility testing. The susceptibility testing of 73 H. pylori strains to the recommended
antimicrobial agents showed that 51.7% of isolates were resistant to one or more drugs, while
49.3% of strains were susceptible to all tested antibiotics/chemotherapeutics. The resistance
rates of H. pylori strains to the assayed antimicrobial agents were presented in Table 3 (data
include strains resistant to one, two or four antibiotics/chemotherapeutics).
The rate of resistance of H. pylori strains to clarithromycin amounted to 23.3% (17/73). Accord‐
ing to the Maastricht/Florence IV Consensus Report, southern Poland should be qualified as
an area of high clarithromycin resistance. Consequently, the use of clarithromycin in H.
pylori infections in this region should be either abandoned (as an empirical treatment) or
applied but only with prior susceptibility testing. Due to this fact, it seems reasonable to change
the current Polish recommendation (PSG-E, 2008) concerning clarithromycin use in the
treatment of H. pylori infections.
Furthermore, the resistance rates to metronidazole and levofloxacin were 39.7% (29/73) and
12.3% (9/73), respectively.
Antimicrobial agents N (%) of resistant strains (n = 73)
Clarithromycin 17 (23.3)
Metronidazole 29 (39.7)
Levofloxacin 9 (12.3)
Amoxicillin 1 (1.4)
Tetracycline 0 (0)
Table 3. Resistance rates of H. pylori to clarithromycin, metronidazole, levofloxacin, amoxicillin, and tetracycline in
southern Poland (the data include strains resistant to one, two or four antibiotics/chemotherapeutics).
We also reported the presence of one strain (1,4%; 1/73) resistant to amoxicillin. Resistance to
amoxicillin is an uncommon phenomenon and it is the first report of an amoxicillin-resistant
strain in southern Poland. All examined H. pylori strains were susceptible to tetracycline.
Moreover, we analysed the co-occurrence of resistance to more than one antimicrobial agent
among H. pylori isolates (Table 4).
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Our studies showed the presence of 35.6% (26/73) of single-resistant, 8% (13/73) of double-
resistant and 1.4% (1) of quadruple-resistant strains (susceptibility testing for each tested
isolate included: clarithromycin, metronidazole, levofloxacin, and amoxicillin).
Antimicrobial agents N (%) of resistant strainsn n=73
single-resistant strains
Clarithromycin 6 (8.2)
Metronidazole 16 (21.9)
Levofloxacin 4 (5.4)
double-resistant strains
Clarithromycin + Metronidazole 9 (12.3)
Metronidazole + Levofloxacin 3 (4.1)
Clarithromycin + Levofloxacin 1 (1.4)
quadruple-resistant strains Clarithromycin + Metronidazole + Levofloxacin +Amoxicillin 1 (1.4)
Table 4. Co-occurrence of resistance to various antibiotics/chemotherapeutics among H. pylori strains isolated in
southern Poland.
The MICs obtained in our study ranged from 0.016 mg/L to 256 mg/L for clarithromycin [Figure
3], from 0.016 mg/L to 256 mg/L for metronidazole [Figure 4], from 0.002 mg/L to 12 mg/L for
levofloxacin [Figure 5], and from 0.016 mg/L to 0.125 mg/L for both amoxicillin [Figure 6] and
tetracycline [Figure 7].
The mean MIC values were as follows: 19.2 mg/L for clarithromycin, 75.2 mg/L for metroni‐
dazole, 0.61 mg/L for levofloxacin, 0.018 mg/L for amoxicillin, and 0.024 mg/L for tetracycline.
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Figure 3. The distribution of clarithromycin MICs among H. pylori strains (Clinical breakpoints according to EUCAST:
resistant MIC>0.5 mg/L; susceptible MIC≤0.25 mg/L); * strains with MIC value of 0.5 mg/L were considered as resistant
to clarithromycin according to the results of PCR–RFLP analysis.
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Figure 4. The distribution of MICs among H. pylori strains (Clinical breakpoints according to EUCAST: resistant MIC>8
mg/L; susceptible MIC≤8 mg/L).
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Figure 5. The distribution of levofloxacin MICs among H. pylori strains (Clinical breakpoints according to EUCAST: re‐
sistant MIC>1 mg/L; susceptible MIC≤1 mg/L).
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Figure 6. The distribution of amoxicillin MICs among H. pylori strains (Clinical breakpoints according to EUCAST: resist‐
ant MIC>0.12 mg/L; susceptible MIC≤0.12 mg/L).
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Figure 7. The distribution of tetracycline MICs among H. pylori strains (Clinical breakpoints according to EUCAST: re‐
sistant MIC>1 mg/L; susceptible MIC≤1 mg/L).
The quantitative E-test method allowed us to observe the dynamically increasing resistance of
H. pylori to antimicrobials during the monitoring.
In Poland, H. pylori resistance rate to clarithromycin exceeded 20% [22, 23, 62]. Our recent study
revealed that this rate remained at the same high level or even increased to 23.3%. Therefore
the current Polish guidelines (PSG–E, 2008) should be changed according to EHSG (2012).
EHSG recommended abandoning clarithromycin in empirical treatment or susceptibility
testing prior to the administration of this drug in regions with high prevalence of resistant H.
pylori strains (>20%).
Moreover, it is worth emphasizing that our study showed that 6.8% of analysed strains
demonstrated high clarithromycin MIC values: 256 mg/L.
Furthermore, we revealed persistent, high-level resistance to metronidazole (39.7% of isolates).
Twenty-six percent of H. pylori strains displayed the metronidazole MIC values as high as 256
mg/L. Additionally, the resistance rate to levofloxacin increased in comparison to our previous
studies (5% in the years 2006-2008 [62] vs. 12.3% currently).
Although the amoxicillin MIC values are still low, emergence of a resistant H. pylori isolate
was a new phenomenon. It was the first amoxicillin-resistant H. pylori strain isolated in
southern Poland.
The reason as to why H. pylori resistance to antibiotics/chemotherapeutics has to be monitored,
are the results of our study. Moreover, in order to obtain effective regimen for the cure of H.
pylori infection, it seems reasonable to perform susceptibility testing prior to the treatment.
PCR identification of H. pylori. Microbiological identification of all 73 H. pylori isolates was
confirmed by PCR targeting the 16S rRNA gene (representative samples are presented in
Figure 8).
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Figure 8. Representative samples of 16S rRNA PCR assay. Lines: 1-11 - selected H. pylori strains isolated from patients
enrolled to the study, 12 - positive control (109 bp), 13 - negative control; M - molecular weight marker (O'GeneRuler
50 bp DNA Ladder, Thermo Scientific, USA).
cagA and vacA genes distribution.cagA and vacA genes have been identified as being
virulence-associated and may have important clinical and epidemiological implications [73].
While cagA is carried by 56-90% of H. pylori strains [8, 24, 29-32], vacA is present in all identified
H. pylori isolates [74]. The occurrence of cagA and vacA genes was tested in all 73 strains.
Figure 9. Representative samples of cagA and vacA genes detection. A) cagA detection: lines: 1-4 - selected H. pylori
strains isolated from patients enrolled to the study, 5 - positive control (298 bp), 6 - negative control; B) vacA detec‐
tion: lines: 7-10 - selected H. pylori strains isolated from patients enrolled to the study, 11 - positive control (229 bp),
12 - negative control; M - molecular weight marker (O'GeneRuler 50 bp DNA Ladder, Thermo Scientific, USA).
The cytotoxin associated gene - cagA - was detected in 80.8% of H. pylori strains (59/73), whereas
cagA-negative strains accounted for 19.2% (14/73) (representative samples are shown in Figure
9). The occurrence of vacA gene was confirmed in 89% (65/73) of strains, while 11% (8/73) of
strains were vacA-negative. The absence of vacA gene in 11% of assayed H. pylori strains was
associated with limited sensitivity of the method used in this study [71].
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Table 5 shows the relationship between the distribution of cagA and vacA genes and the clinical
diagnosis.
Among 19 patients with peptic ulcer disease (PUD), 78.9% (15/19) were infected with H.
pylori cagA-positive strains, while 21.1% (4/19) with strains cagA-negative. Moreover, 84.2%
(16/19) of patients with PUD were infected with H. pylori vacA-positive strains and 15.8% (3/19)
with strains vacA-negative. Double positive H. pylori strains (cagA-positive and vacA-positive)
occurred in 63.2% (12/19) of patients with peptic ulcer disease.
Among the group of patients with NUD, 81.5% (49/54) of isolated H. pylori strains carried
cagA gene, but only 18.5% (10/54) were cagA-negative. Although none of these patients
developed ulceration during the study, it is probable that these infections, if untreated, may
lead to serious consequences such as peptic ulcer disease or even gastric cancer, due to the fact
that the cagA-positive H. pylori strains increase the likelihood of developing these diseases.
The cagA-positive, vacA-positive H. pylori genotype was the most common one in both: groups
of patients: with PUD as well as with NUD, whereas the duble-negative genotype was not
found.
Genotype
N (%) of strains
PUD n=19 NUD n=54
cagA + 15 (78.9) 44 (81.5)
cagA - 4 (21.1) 10 (18.5)
vacA + 16 (84.2) 49 (90.7)
vacA - 3 (15.8) 5 (9.3)
cagA + vacA + 12 (63.2) 39 (72.5)
cagA + vacA - 3 (15.8) 5 (9.3)
cagA - vacA + 4 (21.1) 10 (18.5)
cagA - vacA - 0 (0) 0 (0)
PUD – peptic ulcer disease
NUD – non-ulcer dyspepsia
Table 5. Relationship between distribution of cagA and vacA genes and the clinical diagnosis.
PCR-RFLP analysis of H. pylori resistance to clarithromycin. Molecular analysis of clarithro‐
mycin resistance mechanism was conducted on 73 H. pylori strains. The results of PCR-RFLP
analysis are shown in Figure 10 and Table 6.
Among the 17 clarithromycin-resistant isolates, Eco31I (BsaI) digested PCR amplicons of 12
(70.6%) strains to 304-base-pair and 101-base-pair, indicating that the strains contained A2143G
mutation in the 23S rRNA gene. Furthermore, BbsI enzyme cut products of 3 (17.6%) strains
to 332-base-pair and 93-base-pair suggesting that the isolates had A2142G mutation.
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RFLP analysis of 11.8% (2/17) clarithromycin-resistant isolates gave negative results for both
assayed mutations. Resistance to clarithromycin in these isolates (negative for both A2413G
and A2142G) might be associated with other mutations in the 23S rRNA such as A2142C,
T2245C, T2717C, A2115G, G2141A, T2182G, or T2182C as well as efflux pump [63].
Digestion of PCR products of 100% (56/56) strains not resistant to clarithromycin revealed the
absence of the tested mutations. Moreover, our studies suggest that the presence of A2142G
mutation is more related to the high clarithromycin MIC level than the A2143G mutation.
Type of mutation
N (%) of strains
Clarithromycin–resistant
n=17
Clarithromycin–susceptible
n=56
A2143G 12 (70.6) 0 (0)
A2142G 3 (17.6) 0 (0)
not detected 2 (11.8) 56 (100)
Table 6. Prevalence of A2143G and A2142G mutations in the group of 73 tested H. pylori strains.
7. Conclusions
Results of our studies concerning the resistance rates of H. pylori strains isolated from subjects
in southern Poland suggest the need for constant monitoring of the resistance to a set of
Figure 10. Restriction endonuclease analysis of 23S rRNA amplicons (425 bp) digested with Eco31I (BsaI) and BbsI en‐
zymes. A) detection of A2143G mutation: lines: 1-4 - selected H. pylori strains isolated from patients enrolled to the
study, 5 - positive control (digestion products of 304 and 101 bp), 6 - negative control; B) detection of A2142G muta‐
tion: lines: 7-10 - selected H. pylori strains isolated from patients enrolled to the study, 11 - positive control (digestion
products of 332 and 93 bp), 12 - negative control; M – Molecular Weight Marker (50 bp O’Gene Ruler, Thermo Scien‐
tific, USA).
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antimicrobial agents routinely used for empirical therapy. We observed high level of clari‐
thromycin resistance rate (>20%), which resulted in the necessity of either to abandon clari‐
thromycin in an empirical treatment or to perform susceptibility testing prior to application
of clarithromycin-containing treatment.
We also noted the increase in H. pylori resistance to levofloxacin and persistent high level
resistance to metronidazole, which resulted in the necessity of treatment guided by antimi‐
crobial susceptibility testing.
To conclude, antimicrobial susceptibility testing can improve treatment outcomes and reduce
the outpatient antibiotic consumption, while the introduction of molecular methods for
clarithromycin resistance testing allows better and more efficient management of H. pylori
infections.
8. Further research
Our further investigations will be concerned with the application of the PCR-RFLP method in
detection of less frequent 23S rRNA gene mutations associated with clarithromycin resistance.
Furthermore, we will focus on direct detection of H. pylori in biopsy specimens as well as
characterization of the resistance determinants.
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